Clinical trials in the pandemic age : What is fit for purpose?
Copyright: © 2020 Hartman D et al..
It is critical to ensure that COVID-19 studies provide clear and timely answers to the scientific questions that will guide us to scalable solutions for all global regions. Significant challenges in operationalizing trials include public policies for managing the pandemic, public health and clinical capacity, travel and migration, and availability of tests and infrastructure. These factors lead to spikes and troughs in patient count by location, disrupting the ability to predict when or if a trial will reach recruitment goals. The focus must also be on understanding how to provide equitable access to these interventions ensuring that interventions reach those who need them the most, be it patients in low resource settings or vulnerable groups. We introduce a website to be used by The Bill & Melinda Gates Foundation, Wellcome Trust, and other funders of the COVID Therapeutics Accelerator that accept proposals for future clinical research. The portal enables evaluations of clinical study applications that focus on study qualities most likely to lead to informative outcomes and completed studies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:4 |
|---|---|
| Enthalten in: |
Gates open research - 4(2020) vom: 18., Seite 58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hartman, Dan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 28.09.2020 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.12688/gatesopenres.13146.1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM312332025 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM312332025 | ||
| 003 | DE-627 | ||
| 005 | 20231225144205.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12688/gatesopenres.13146.1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1041.xml |
| 035 | |a (DE-627)NLM312332025 | ||
| 035 | |a (NLM)32656501 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Hartman, Dan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical trials in the pandemic age |b What is fit for purpose? |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 28.09.2020 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright: © 2020 Hartman D et al. | ||
| 520 | |a It is critical to ensure that COVID-19 studies provide clear and timely answers to the scientific questions that will guide us to scalable solutions for all global regions. Significant challenges in operationalizing trials include public policies for managing the pandemic, public health and clinical capacity, travel and migration, and availability of tests and infrastructure. These factors lead to spikes and troughs in patient count by location, disrupting the ability to predict when or if a trial will reach recruitment goals. The focus must also be on understanding how to provide equitable access to these interventions ensuring that interventions reach those who need them the most, be it patients in low resource settings or vulnerable groups. We introduce a website to be used by The Bill & Melinda Gates Foundation, Wellcome Trust, and other funders of the COVID Therapeutics Accelerator that accept proposals for future clinical research. The portal enables evaluations of clinical study applications that focus on study qualities most likely to lead to informative outcomes and completed studies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a master protocol | |
| 650 | 4 | |a pandemic | |
| 650 | 4 | |a post-exposure prophylaxis | |
| 650 | 4 | |a pre-exposure prophylaxis | |
| 650 | 4 | |a real-world evidence | |
| 650 | 4 | |a safety and efficacy | |
| 700 | 1 | |a Heaton, Penny |e verfasserin |4 aut | |
| 700 | 1 | |a Cammack, Nick |e verfasserin |4 aut | |
| 700 | 1 | |a Hudson, Ian |e verfasserin |4 aut | |
| 700 | 1 | |a Dolley, Shawn |e verfasserin |4 aut | |
| 700 | 1 | |a Netsi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Norman, Thea |e verfasserin |4 aut | |
| 700 | 1 | |a Mundel, Trevor |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Gates open research |d 2017 |g 4(2020) vom: 18., Seite 58 |w (DE-627)NLM280169531 |x 2572-4754 |7 nnns |
| 773 | 1 | 8 | |g volume:4 |g year:2020 |g day:18 |g pages:58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12688/gatesopenres.13146.1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 4 |j 2020 |b 18 |h 58 | ||